Wondering how your practice’s use of next-generation retinal agents compares to the experts? Join Dr. Durga Borkar and Dr. Veeral Sheth as they discuss how they are using next-generation agents to free their patients from frequent office visits.

Need to catch up on the latest data surrounding next-generation retinal treatments? Drs. Veeral Sheth and Durga Borkar walk through the most recent efficacy and safety data around faricimab, aflibercept 8 mg, and the PDS with ranibizumab. They also review the latest insights on the use of these treatments in real-world practice.

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Marianne Silkjaer Nielsen. Not only is Ms. Nielsen the mother of a girl who lives with immune complex-MPGN, but she’s also the founder of CompCure, a not-for-profit association that is dedicated to improving outcomes in patients with C3G and immune complex-MPGN.

Together, their conversation will cover:

• The Diagnostic Journey: Rare diseases often have a long diagnostic journey. A specialized pathologist is often needed to identify the disease, and many patients are not diagnosed until they have severe symptoms.
  
• Therapeutic Challenges: The realization that there is no cure or disease-modifying therapy can be devastating. Furthermore, the lack of widespread experience in these rare diseases among physicians, coupled with a lack of long-term evidence, can lead to suboptimal care and poor outcomes.
  
• Impact of Delayed Treatment: Also discussed is the importance of screening programs for kidney diseases and access to targeted therapies—which until now, were not available—before critical illness sets in.
  
• Future Outlook and Advocacy:

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Dr. Anne-Marie van de Kar, Professor of Pediatrics at Radboud University Medical Center in the Netherlands, to discuss the role of complement in C3 glomerulopathy (C3G). They begin by defining C3G and exploring its pathophysiology, specifically focusing on the overactivation of the alternative pathway of the complement system.

Then, Drs. Nester and van de Kar delve into the specifics of why the alternative pathway is so central to C3G, including the role of autoantibodies like C3 nephritic factor (C3Nef) and genetic factors. Their discussion also covers the importance of diagnostic testing, including the role of kidney biopsies and biomarker analysis to identify the underlying cause and guide treatment, as well as the limitations of current C5 inhibition therapies and the promise of new treatments that target C3 activation directly.

This episode is supported by Apellis & Sobi.

Join our experts as they examine the integration of perioperative immune checkpoint inhibitors (ICIs) in the management of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC). Drs. Le Tourneau and Harrington discuss unmet needs and limitations of current treatment and review data from trials supporting the use of perioperative ICIs, emphasizing their event-free survival and pathologic response outcomes. The conversation also addresses multidisciplinary coordination and considerations for managing immune-related adverse events. Variations in treatment guidelines, access, and clinical practice between the US, Europe, and other regions are explored to contextualize the challenges of global implementation and provide strategies for practitioners to improve care.

Neuropsychiatric symptoms (NPS) associated with Alzheimer’s disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. This broadcast replay will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.

In this episode of Clinical Countdown, Professors Jonathan Barratt and Sydney Tang discuss the evolving treatment strategies for IgA nephropathy, focusing on lowering proteinuria through combination therapy. They examine differences in disease presentation across global populations and emphasize updated KDIGO guidance on aggressive proteinuria reduction targets. The discussion includes evidence from the PROTECT trial supporting sparsentan’s efficacy as a dual endothelin–angiotensin receptor antagonist and considers the role of SGLT2 inhibitors based on outcomes from the DAPA-CKD and EMPA-KIDNEY trials. Our experts also review recent real-world data showing that when added to SGLT2 inhibitors and RAS blockade, sparsentan can significantly reduce proteinuria without notable safety concerns.

Join our expert panel as they explore the evolving treatment landscape of resectable locally advanced head and neck squamous cell carcinoma. Learn how perioperative immune checkpoint inhibitors are improving event-free survival and get practical insights on applying this data to clinical care. The discussion highlights the importance of early multidisciplinary collaboration and offers perspectives on patient selection, treatment timing, and managing adverse events. Don’t miss this opportunity to enhance your approach to reducing recurrence and disease progression in your patients.

This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.